SGLT2 Inhibitors for Type 2 Diabetes Triple DKA Risk- Study
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors used for the treatment of type 2 diabetes, and for heart failure, are associated with a nearly threefold increased risk for diabetic ketoacidosis (DKA), according to a newlarge database analysis.

This study aimed to assess whether SGLT-2 inhibitors, compared with dipeptidyl peptidase-4 (DPP-4) inhibitors, are associated with an increased risk for DKA in patients with type 2 diabetes.

A Population-based cohort study involved electronic health care databases from 7 Canadian provinces and the United Kingdom from which 208757 new users of SGLT-2 inhibitors were matched by using time-conditional propensity scores to 208757 recipients of DPP-4 inhibitors.

Results:
-- Overall, 521 patients were diagnosed with DKA during 370 454 person-years of follow-up.
-- Compared with DPP-4 inhibitors, SGLT-2 inhibitors were associated with an increased risk for DKA (incidence rate, 2.03 versus 0.75, respectively.
-- Molecule-specific HRs were 1.86 for dapagliflozin, 2.52 for empagliflozin, and 3.58 for canagliflozin.
-- Age and sex did not modify the association; prior receipt of insulin appeared to decrease the risk.

Conclusively, SGLT-2 inhibitors were associated with an almost 3-fold increased risk for DKA, with molecule-specific analyses suggesting a class effect.

Source: https://www.acpjournals.org/doi/10.7326/M20-0289
Dr. N●●●i D●●●●r and 4 others like this1 share
Like
Comment
Share
Dr. J●●a J●●n
Dr. J●●a J●●n Biochemistry
Nice
Jul 30, 2020Like